Mounjaro is used for type 2 diabetes, while Zepbound is approved for weight loss
Since 2025, GLP - 1 pharmaceutical companies have collectively embraced out - of - hospital retail and online e - commerce channels, competing for scenarios and traffic, and sponsoring various "national weight - loss" and "scientific weight - loss" activities
Healthcare law firms analyzing the question conclude that a salt-form change does not create meaningful legal differentiation under the "essentially a copy" doctrine, the same reasoning the FDA uses to prevent minor modifications from circumventing drug regulations
Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
Zhu L, Huang Y, Edirisinghe I, Park E, Burton-Freeman B